Fig. 4

Effect of CD200R1 agonist administration on dopaminergic degeneration in the acute MPTP mouse model. a Experimental design. Mice were injected intraperitoneally with saline or MPTP (20 mg/kg) every 2 h to a total of 4 doses in 1 day. In mice treated with the CD200R1 agonist, 1.8 mg/kg or 3.6 mg/kg CD200Fc were intraperitoneally administered twice, 30 min before the first MPTP injection and 24 h after the last one. Isotype administration regimen was the same as for CD200Fc. Mice were sacrificed 7 days (d) following the last MPTP injection and brains were fixed for immunohistochemistry (IHC). b TH immunostaining in striatum and optical densitometry of striatal TH-positive dopaminergic fibers of saline, MPTP, CD200Fc + MPTP and isotype+MPTP, considering the lowest dose (1.8 mg/kg) (c) and the highest dose (3.6 mg/kg) (d) of CD200Fc. e TH immunostaining and stereological cell counts of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of saline, MPTP, CD200Fc + MPTP and isotype+MPTP, considering the lowest dose (1.8 mg/kg) (f) and the highest dose (3.6 mg/kg) (g) of CD200Fc. Bars are means + SEM of five to eight mice per experimental group. **p < 0.01 and ***p < 0.001 vs. saline; one-way ANOVA and Newman-Keuls post hoc test. Scale bars: 500 μm (striatum) and 200 μm (SNpc)